

Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes

*Jacob T. Maddux, MD; Jonathan W. Inselman, MS; Molly M. Jeffery, PhD;
Regina W. Lam, BA; Nilay D. Shah, PhD; and Matthew A. Rank, MD*

CHEST 2021; 159(3):924-932

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

© 2020 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1016/j.chest.2020.10.050

e-Table 1

Drug	Criteria	Days Supply
Omalizumab	If have 3 fills within < 3 weeks of previous fill	2 weeks
	If have 2 or less fills within < 3 weeks of previous fill	4 weeks
Mepolizumab	ANY	4 weeks
Reslizumab	ANY	4 weeks
Dupilumab	ANY	Count of days supply variable from pharmacy claim
Benralizumab	First 3 fills	4 weeks
	fill 4 and later	8 weeks